Cancer vaccine-MUC 1…rapeutics) Drug Due Diligence 2026

This Cancer vaccine-MUC 1(Vaxil Biotherapeutics) Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 11 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Cancer vaccine-MUC 1(Vaxil Biotherapeutics) can convert its Therapeutic vaccine profile and MUC1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Cancer vaccine-MUC 1(Vaxil Biotherapeutics) (query alias: Cancer vaccine-MUC 1(Vaxil Biotherapeutics))
Modality / target	Therapeutic vaccine; MUC1; MUC1 inhibitors
Highest global status	Phase 2
Originator	Vaxil Biotherapeutics Ltd.
Active developers	Vaxil Biotherapeutics Ltd., Hadassah Foundation

The MCP disease footprint includes Breast Cancer, Multiple Myeloma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
ChiCTR1800017638	Phase 1	Not yet recruiting	2	Primary endpoint not disclosed in English source
ChiCTR1800017644	Phase 1	Not yet recruiting	2	Primary endpoint not disclosed in English source
ChiCTR1800014927	Phase 1/2	Recruiting	10	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Abstract P5-04-02: Safety and efficacy from first-in-human immunotherapy combining NK and T cell activation with off-the-shelf high-affinity CD16 NK cell line (haNK) in patients with 2

Phase 1; n=9; evaluation: Positive. Reported fields: Adverse Event: SAEs = No SAEs were attributed to investigational agents

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Cancer vaccine-MUC 1(Vaxil Biotherapeutics) addresses Breast Cancer, Multiple Myeloma. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Therapeutic vaccine—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 14 matched transaction record(s) under the scope “target-level comparable: MUC1.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: MUC1 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2025-01-13	Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH	Pending	US$132.5M stated total
2023-08-07	Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida’s Commitment to Redefining Cancer Cell Therapy	Phase 1	Financial terms not disclosed
2021-03-26	Qilu Pharmaceutical and Peptron Sign License Agreement for anti-MUC1 ADC	Preclinical	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Antibodies directed against signal peptides, methods and uses thereof”. The milestone feed surfaced a patent-application signal described as “Antigen specific multi epitope vaccines”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Immunogenicity durability and clinically meaningful protection
Population selection, endpoint timing, and comparator relevance
Manufacturing consistency, distribution, and uptake

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO